COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration. Issue 11 (28th October 2020)

• Record Type: Journal Article
• Authors: Hilbrands, Luuk B; Duivenvoorden, Raphaël; Vart, Priya; Franssen, Casper F M; Hemmelder, Marc H; Jager, Kitty J; Kieneker, Lyanne M; Noordzij, Marlies; Pena, Michelle J; Vries, Hanne de; Arroyo, David; Covic, Adrian; Crespo, Marta; Goffin, Eric; Islam, Mahmud; Massy, Ziad A; Montero, Nuria; Oliveira, João P; Roca Muñoz, Ana; Sanchez, J Emilio; Sridharan, Sivakumar; Winzeler, Rebecca; Gansevoort, Ron T
• Is Part Of: Nephrology dialysis transplantation. Volume 35:Issue 11(2020)
• Page Start: 1973
• Page End: 1983
• Publication Date: 2020-10-28
• Subjects: COVID-19 -- dialysis -- kidney -- mortality -- transplantation; Nephrology -- Periodicals; Hemodialysis -- Periodicals; Kidneys -- Transplantation -- Periodicals; Hemodialysis; Kidneys -- Transplantation; Nephrology; Periodicals; 616.61
• DOI: 10.1093/ndt/gfaa261
• Languages: English
• ISSNs: 0931-0509

Abstract

Abstract: Background. Patients on kidney replacement therapy comprise a vulnerable population and may be at increased risk of death from coronavirus disease 2019 (COVID-19). Currently, only limited data are available on outcomes in this patient population. Methods. We set up the ERACODA (European Renal Association COVID-19 Database) database, which is specifically designed to prospectively collect detailed data on kidney transplant and dialysis patients with COVID-19. For this analysis, patients were included who presented between 1 February and 1 May 2020 and had complete information available on the primary outcome parameter, 28-day mortality. Results. Of the 1073 patients enrolled, 305 (28%) were kidney transplant and 768 (72%) dialysis patients with a mean age of 60 ± 13 and 67 ± 14 years, respectively. The 28-day probability of death was 21.3% [95% confidence interval (95% CI) 14.3–30.2%] in kidney transplant and 25.0% (95% CI 20.2–30.0%) in dialysis patients. Mortality was primarily associated with advanced age in kidney transplant patients, and with age and frailty in dialysis patients. After adjusting for sex, age and frailty, in-hospital mortality did not significantly differ between transplant and dialysis patients [hazard ratio (HR) 0.81, 95% CI 0.59–1.10, P = 0.18]. In the subset of dialysis patients who were a candidate for transplantation ( n = 148), 8 patients died within 28 days, as compared with 7 deaths in 23 patients who underwent a kidney transplantation <1 year before presentation (HR adjusted for sex, age and frailty 0.20, 95% CI 0.07–0.56, P < 0.01). Conclusions. The 28-day case-fatality rate is high in patients on kidney replacement therapy with COVID-19 and is primarily driven by the risk factors age and frailty. Furthermore, in the first year after kidney transplantation, patients may be at increased risk of COVID-19-related mortality as compared with dialysis patients on the waiting list for transplantation. This information is important in guiding clinical decision-making, and for informing the public and healthcare authorities on the COVID-19-related mortality risk in kidney transplant and dialysis patients.